Therapy Detail

Therapy Name CPI-006 + CPI-444
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CPI-006 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 Limited information is currently available on CPI-006 a putative monoclonal antibody against NT5E (CD73) (Jul 2018).
CPI-444 V81444 Immune Checkpoint Inhibitor 99 CPI-444 binds to and inhibits A2A (ADORA2A) on immune cells, which may increase anti-tumor immune response and inhibit tumor growth by blocking binding of the immunosuppressive metabolite, adenosine (Cancer Immunol Res 2016;4(11 Suppl):Abstract nr PR04, PMID: 29923026).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting